Get the Stockscreener App
4.11
13.85%
0.50
After Hours:
4.15
0.04
+0.97%
Savara Inc stock is traded at $4.11, with a volume of 2.61M.
It is up +13.85% in the last 24 hours and up +16.43% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.61
Open:
$3.65
24h Volume:
2.61M
Relative Volume:
1.93
Market Cap:
$710.36M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-12.45
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+20.53%
1M Performance:
+16.43%
6M Performance:
+36.54%
1Y Performance:
+9.31%
1-Day Range:
$3.60
$4.12
1-Week Range:
$3.36
$4.12
52-Week Range:
$1.89
$4.295
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
4.11 | 623.94M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.10 | 106.87B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
491.22 | 63.14B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.77 | 61.27B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
849.46 | 51.94B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
167.91 | 35.04B | 398.11M | -1.03B | -868.57M | -5.7032 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Aug EndMonth: How geopolitical risks impact Savara Inc. (YB4P) stockStop Loss & Weekly High Return Stock Forecasts - nchmf.gov.vn
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - ACCESS Newswire
Shareholders SueWallSt in New Class Action Against Savara Inc.Act Now - ACCESS Newswire
How geopolitical risks impact Savara Inc. (YB4P) stockWeekly Investment Summary & Community Consensus Picks - nchmf.gov.vn
Levi & Korsinsky Reminds Savara Inc. Investors of the - GlobeNewswire
Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRA - FinancialContent
Pattern recognition hints at Savara Inc. upsideWeekly Trading Summary & Verified Momentum Watchlists - newser.com
SVRA Investors Have Opportunity to Lead Savara Inc. Securities F - GuruFocus
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Savara Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsSVRA - MarketScreener
Class Action Filed Against Savara Inc. (SVRA) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Class Action Lawsuit Filed Against Savara Inc. (SVRA)Recover LossesContact Levi & Korsinsky Before November 7, 2025 - ACCESS Newswire
Why Savara Inc. is moving todayGap Up & Verified Stock Trade Ideas - newser.com
Is Savara Inc. stock recession proofJuly 2025 Gainers & Community Verified Trade Signals - nchmf.gov.vn
How analysts revise price targets for Savara Inc. (YB4P) stockJuly 2025 Technicals & High Accuracy Buy Signal Tips - nchmf.gov.vn
SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to ... - Bluefield Daily Telegraph
SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th Deadline - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain OfficersSVRA - PR Newswire
Rate Hike: How analysts revise price targets for Savara Inc. (YB4P) stockCPI Data & Pattern Based Trade Signal System - nchmf.gov.vn
Why Savara Inc. stock could benefit from AI revolutionTrade Ideas & Short-Term High Return Strategies - nchmf.gov.vn
Savara promotes Yasmine Wasfi to chief medical officer By Investing.com - Investing.com Nigeria
SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Q3 Earnings Forecast for Savara Issued By Lifesci Capital - Defense World
Savara promotes Yasmine Wasfi to chief medical officer - Investing.com
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025SVRA - cnhinews.com
Savara promotes Wasfi to Chief Medical Officer - TipRanks
Savara Announces Chief Medical Officer (CMO) Transition - The Joplin Globe
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - ACCESS Newswire
Faruqi & Faruqi Reminds Savara Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025SVRA - FinancialContent
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SVRA LAWSUIT ALERT: The Gross Law Firm Notifies Savara Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - WV News
SVRA Shareholders Have Opportunity to Lead Savara Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to - GlobeNewswire
SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to Contact Kirby McInerney LLP Before ... - Bluefield Daily Telegraph
Savara Inc. (SVRA) Shareholders Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Savara, Inc.: A Deep Dive (NASDAQ:SVRA) - Seeking Alpha
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - Morningstar
SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
Lost Money on Savara Inc. (SVRA)? Join Class Action Before November 7, 2025Contact Levi & Korsinsky - ACCESS Newswire
November 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SVRA - MarketScreener
Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 - ACCESS Newswire
Securities Lawsuit Alert: Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - ACCESS Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit - PR Newswire
Securities Fraud Class Action Filed Against Savara Inc. (SVRA)Levi & Korsinsky Reminds Investors of November 7, 2025 - ACCESS Newswire
November 7, 2025 Deadline Approaching: Join Class Action Against Savara Inc. (SVRA)Contact Levi & Korsinsky - ACCESS Newswire
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - GlobeNewswire
SAVARA ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
2.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):